| Original language | English |
|---|---|
| Pages (from-to) | 390-391 |
| Number of pages | 2 |
| Journal | The Lancet Gastroenterology and Hepatology |
| Volume | 7 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2022 |
Funding
| Funders | Funder number |
|---|---|
| Prometheus Laboratories | |
| Reistone Biopharma | |
| TechLab | |
| Eli Lilly and Company | |
| Pfizer | |
| Roche | |
| Gilead Sciences | |
| AbbVie | |
| Meso Scale Diagnostics | |
| Takeda Pharmaceutical Company | |
| Janssen Pharmaceuticals | |
| Fresenius Kabi | |
| Arrien Pharmaceuticals |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Lancet Gastroenterology and Hepatology, Vol. 7, No. 5, 05.2022, p. 390-391.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Difficult-to-treat inflammatory bowel disease
T2 - results from a global IOIBD survey
AU - Parigi, Tommaso Lorenzo
AU - D'Amico, Ferdinando
AU - Abreu, Maria T.
AU - Rubin, David T.
AU - Dignass, Axel
AU - Dotan, Iris
AU - Jairath, Vipul
AU - Magro, Fernando
AU - Peyrin-Biroulet, Laurent
AU - Ghosh, Subrata
AU - Danese, Silvio
N1 - Funding Information: MTA has served as a trainer or lecturer for Prime CME, Janssen Pharmaceuticals, Focus Medical Communications, Cornerstones Health, and Imedex; and as a consultant or adviser to Boehringer Ingelheim, Gilead Sciences, Prometheus Biosciences, Takeda, UCB Biopharma, Eli Lilly, Bellatrix Pharmaceuticals, AbbVie, and Bristol Myers Squibb (BMS). DTR has received grant support from Takeda, and has served as a consultant for AbbVie, AbGenomics, Biomica, Boehringer Ingelheim, BMS, Celgene/Syneos, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, GlaxoSmithKline Services, Ichnos Sciences, InDex Pharmaceuticals, Janssen Pharmaceuticals, Eli Lilly, Pfizer, Prometheus Laboratories, Reistone Biopharma, and TechLab. AD has received research support from or acted as a principal investigator for AbbVie, Dr Falk Pharma, Celgene/BMS, Gilead Sciences/Galapagos, Janssen Pharmaceuticals, Otsuka Pharmaceutical, and Takeda; he has acted as a consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene/BMS, Celltrion, Dr Falk Pharma, Ferring Pharmaceuticals, Fresenius Kabi, Janssen Pharmaceuticals, Merck Sharp & Dohme (MSD), Otsuka Pharmaceutical, Pfizer, Roche, Takeda, Tillotts Pharma, Pharmacosmos, and Vifor Pharma; and has participated in speaker bureaus for AbbVie, Falk Foundation, Ferring Pharmaceuticals, Janssen Pharmaceuticals, Med Update, MSD, Otsuka Pharmaceutical, Pfizer, Roche, Takeda, Eli Lilly, Tillotts Pharma, and Vifor Pharma. ID has received consultation fees from Takeda Pharmaceutical, Janssen Pharmaceuticals, AbbVie, Pfizer, Ferring Pharmaceuticals, Roche/Genentech, Cambridge Healthcare, Celgene/BMS, Dr Falk Pharma, Ierative Scopes, Rafa Laboratories, Neopharm, Nestle, Arena Pharmaceuticals, Gilead Sciences, Galapagos, MSD, Celltrion, Sublimity Therapeutics, Sandoz, Abbott Laboratories, and Athos Therapeutics. VJ has received consulting and advisory board fees from AbbVie, Alimentiv (formerly Robarts Clinical Trials), Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris Pharmaceuticals, BMS, Celltrion, Eli Lilly, Ferring Pharmaceutical, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead Sciences, Janssen Pharmaceuticals, Merck, Mylan, Pandion Therapeutics, Pendopharm, Pfizer, Protagonist Therapeutics, Reistone Biopharma, Roche, Sandoz, Second Genome, Takeda, Teva Pharmaceuticals, Topivert Pharma, and Vividion Therapeutics; and speaker's fees from AbbVie, Ferring Pharmaceuticals, Galapagos, Janssen Pfizer Shire, Takeda, and Fresenius Kabi. FM has served as a speaker and received honoraria from MSD, AbbVie, Vifor Pharma, Dr Falk Pharma, Laboratorios Vitoria, Ferring Pharmaceuticals, Hospira, and Biogen. LP-B reports personal fees from Galapagos, AbbVie, Janssen Pharmaceuticals, Genentech, Alimentiv, Ferring Pharmaceuticals, Tillots Pharma, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena Pharmaceuticals, Gilead Sciences, Amgen, BMS, Vifor Pharma, Norgine, Mylan, Eli Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, and Thermo Fisher; grants from AbbVie, MSD, Takeda, and Fresenius Kabi; and stock options from Clinical Trials Mobile Application. SG declares consulting fees from Pfizer, Janssen Pharmaceuticals, AbbVie, Takeda, BMS, Receptos, Celgene, Gilead Sciences, Eli Lilly, and Boehringer Ingelheim; and speaker fees from AbbVie, Janssen Pharmaceuticals, Takeda, Ferring Pharmaceuticals, Shield Therapeutics, and Dr Falk Pharma. SD has served as a speaker and consultant for Schering-Plough, AbbVie, Actelion, Alfa Wasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring Pharmaceuticals, Genentech, Grünenthal, Johnson & Johnson, Millennium Takeda, MSD, Nikkiso Europe, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma, and Vifor Pharma; and an advisory board member for AbbVie and Ferring Pharmaceuticals. TLP and FD'A declare no competing interests.
PY - 2022/5
Y1 - 2022/5
UR - http://www.scopus.com/inward/record.url?scp=85127466741&partnerID=8YFLogxK
U2 - 10.1016/S2468-1253(22)00085-1
DO - 10.1016/S2468-1253(22)00085-1
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???
C2 - 35397241
AN - SCOPUS:85127466741
SN - 2468-1253
VL - 7
SP - 390
EP - 391
JO - The Lancet Gastroenterology and Hepatology
JF - The Lancet Gastroenterology and Hepatology
IS - 5
ER -